7
First patient dosed in BUOY-1 study targeting MDD with or without anxious distress
Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodrug of allopregnanolone, for major depressive disorder (MDD) with or without anxious distress.
GlyphAllo is designed to overcome limitations of allopregnanolone, a molecule known for its rapid antidepressant and anxiolytic effects.
The BUOY-1 study builds on successful phase 1 and phase 2a data and will assess the efficacy, safety and tolerability of GlyphAllo in up to 360 adults over six weeks….